These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 18525044)

  • 1. Chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    N Engl J Med; 2008 Jun; 358(23):2482-94. PubMed ID: 18525044
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.
    Gralla R
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):507-8. PubMed ID: 17147235
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurokinin antagonism and chemotherapy-induced emesis.
    Shanahan F; O'Sullivan GC
    Am J Gastroenterol; 1999 Nov; 94(11):3368-9. PubMed ID: 10566748
    [No Abstract]   [Full Text] [Related]  

  • 5. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic drugs.
    Cranwell-Bruce L
    Medsurg Nurs; 2009; 18(5):309-13; quiz 314. PubMed ID: 19927970
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist].
    Nieber K; Schoppmeyer K
    Pharm Unserer Zeit; 2007; 36(5):373-80. PubMed ID: 17722144
    [No Abstract]   [Full Text] [Related]  

  • 10. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced nausea and vomiting.
    Lohr L
    Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCCN antiemesis guidelines emphasize 'delayed' emesis, new 5-HT3 inhibitors, and NK-1 blockers.
    National Comprehensive Cancer Network (NCCN)
    J Support Oncol; 2004; 2(4):366. PubMed ID: 15357520
    [No Abstract]   [Full Text] [Related]  

  • 14. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
    Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting nausea in the '90s: more and better anti-emetics can help.
    Saphir A
    J Natl Cancer Inst; 1997 Sep; 89(17):1252-5. PubMed ID: 9293911
    [No Abstract]   [Full Text] [Related]  

  • 17. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
    Sarcev T; Secen N; Zaric B; Milovancev A
    J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.